Epidemiology of Benign Prostatic Hyperplasia and Comorbidities in Racial and Ethnic Minority Populations

American Journal of Medicine

Volumn 121, Issue 8 SUPPL.2, 2008, Pages

  Hoke, Gerald P ^a   McWilliams, Glen W ^b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

African American; Benign prostatic hyperplasia; Comorbidities; Incidence; Latino; Prostate

Indexed keywords

ANDROGEN RECEPTOR;

AFRICAN AMERICAN; ARTICLE; CARDIOVASCULAR DISEASE; CAUCASIAN; CELL COMPOSITION; COMORBIDITY; DIABETES MELLITUS; ERECTILE DYSFUNCTION; ETHNIC DIFFERENCE; ETHNICITY; HEALTH CARE ACCESS; HEREDITY; HISPANIC; HUMAN; HYPERTENSION; LOGISTIC REGRESSION ANALYSIS; LOWER URINARY TRACT SYMPTOM; MEDICAL RESEARCH; METABOLIC DISORDER; METABOLIC SYNDROME X; PATHOGENESIS; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RACE DIFFERENCE; RISK FACTOR; SIGNAL TRANSDUCTION; UNITED STATES;

AFRICAN AMERICANS; AGED; AGED, 80 AND OVER; COMORBIDITY; HISPANIC AMERICANS; HUMANS; INCIDENCE; LIFE STYLE; MALE; PROSTATIC HYPERPLASIA; RECEPTORS, ANDROGEN; RISK FACTORS; SEVERITY OF ILLNESS INDEX; UNITED STATES; URINATION DISORDERS;

EID: 48149109454     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2008.05.021     Document Type: Article

References (60)

1. Platz E.A., Smit E., Curhan G.C., Nyberg L.M., and Giovannucci E. Prevalence of and racial/ethnic variation in lower urinary tract symptoms and noncancer prostate surgery in US men. Urology 59 (2002) 877-883
2. Da Silva F.C. Benign prostatic hyperplasia: natural evolution versus medical treatment. Eur Urol 32 suppl 2 (1997) 34-37
3. Roehrborn C.G., Marks L., and Harkaway R. Enlarged prostate: a landmark national survey of its prevalence and impact on US men and their partners. Prostate Cancer Prostatic Dis 9 (2006) 30-34
4. Collins M.F., Friedman R.H., Ash A., Hall R., and Moskowitz M.A. Underdetection of clinical benign prostatic hyperplasia in a general medical practice. J Gen Intern Med 11 (1996) 513-518
5. Naslund M.J., Gilsenan A.W., Midkiff K.D., Bown A., Wolford E.T., and Wang J. Prevalence of lower urinary tract symptoms and prostate enlargement in the primary care setting. Int J Clin Pract 61 (2007) 1437-1445
6. Wong S.Y., Hong A., Leung J., Kwok T., Leung P.C., and Woo J. Lower urinary tract symptoms and depressive symptoms in elderly men. J Affect Disord 96 (2006) 83-88
7. Kuritzky L. Role of primary care clinicians in the diagnosis and treatment of LUTS and BPH. Rev Urol 6 suppl 9 (2004) S53-S59
8. Saigal C.S., and Joyce G. Economic costs of benign prostatic hyperplasia in the private sector. J Urol 173 (2005) 1309-1313
9. Census bureau projects tripling of Hispanic and Asian populations in 50 years; non-hispanic whites may drop to half of total population [press release]. Washington DC: US Census Bureau News, US Dept of Commerce; March 18, 2004. http://www.census.gov/Press-Release/www/releases/archives/population/001720.html Accessed November 30, 2006
10. Naslund M.J., Issa M.M., Grogg A.L., Eaddy M.T., and Black L. Clinical and economic outcomes in patients treated for enlarged prostate. Am J Manag Care 12 suppl (2006) S111-S116
11. Platz E.A., Kawachi I., Rimm E.B., Willet W.C., and Giovannuci E. Race, ethnicity and benign prostatic hyperplasia in the Health Professionals Follow-up Study. J Urol 163 (2000) 490-495
12. Wei J.T., Schottenfeld D., Cooper K., et al. The natural history of lower urinary tract symptoms in black American men: relationships with aging, prostate size, flow rate and bothersomeness. J Urol 165 (2001) 1521-1525
13. Sarma A., McLaughlin J.C., Jacobsen S.J., et al. Longitudinal changes in lower urinary tract symptoms among a cohort of black American men: the Flint Men's Health Study. Urology 64 (2004) 959-965
14. Lee A.J., Garraway W.M., Simpson R.J., Fisher W., and King D. The natural history of untreated lower urinary tract symptoms in middle-aged and elderly men over a period of five years. Eur Urol 34 (1998) 325-332
15. Joseph M.A., Harlow S.D., Wei J.T., et al. Risk factors for lower urinary tract symptoms in a population-based sample of African-American men. Am J Epidemiol 157 (2003) 906-914
16. Henderson B.E., Bernstein L., Ross R.K., Depue R.H., and Judd H.L. The early in utero oestrogen and testosterone environment of blacks and whites: potential effects on male offspring. Br J Cancer 57 (1988) 216-218
17. McConnell J.D. The pathophysiology of benign prostatic hyperplasia. J Androl 12 (1991) 356-363
18. Ingles S.A., Ross R.K., Yu M.C., et al. Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J Natl Cancer Inst 89 (1997) 166-170
19. Giovannucci E., Platz E.A., Stampfer M.J., et al. The CAG repeat within the androgen receptor gene and benign prostatic hyperplasia. Urology 53 (1999) 121-125
20. Mitsumori K., Terai A., Oka H., et al. Androgen receptor CAG repeat length polymorphism in benign prostatic hyperplasia (BPH): correlation with adenoma growth. Prostate 41 (1999) 253-257
21. Nelson K.A., and Witte J.S. Androgen receptor CAG repeats and prostate cancer. Am J Epidemiol 155 (2002) 883-890
22. Pettaway C.A. Racial differences in the androgen/androgen receptor pathway in prostate cancer. J Natl Med Assoc 91 (1999) 653-660
23. Wu A.H., Whittemore A.S., Kolonel L.N., et al. Serum androgens and sex hormone-binding globulins in relation to lifestyle factors in older African-American, white, and Asian men in the United States and Canada. Cancer Epidemiol Biomarkers Prev 4 (1995) 735-741
24. McNeal J. Pathology of benign prostatic hyperplasia: insight into etiology. Urol Clin North Am 17 (1990) 477-486
25. Aoki Y., Arai Y., Maeda H., Okubo K., and Shinohara K. Racial differences in cellular composition of benign prostatic hyperplasia. Prostate 49 (2001) 243-250
26. AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: diagnosis and treatment recommendations. J Urol. 170 (2003) 530-547
27. Gonzalez R.R., and Kaplan S.A. First-line treatment for symptomatic benign prostatic hyperplasia: is there a particular patient profile for a particular treatment?. World J Urol 24 (2006) 360-366
28. Rosen R.C., Giuliano F., and Carson C.C. Sexual dysfunction and lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Eur Urol 47 (2005) 824-837
29. Rosen R., Altwein J., Boyle P., et al. Lower urinary tract symptoms and male sexual dysfunction: the Multinational Survey of the Aging Male (MSAM-7). Eur Urol 44 (2003) 637-649
30. Gomery P., Bullock A., McGettigan J., et al. Tadalafil is efficacious in Black American and Hispanic men with erectile dysfunction: results from multiple observations in men with erectile dysfunction in national tadalafil study in the US (MOMENTUS). [published correction appears in Int J Impot Res. 2007;19:339]. Int J Impot Res 19 (2007) 76-83
31. Enger S.M., Van Den Eeden S.K., Sternfeld B., et al. California Men's Health Study (CMHS): a multiethnic cohort in a managed care setting. BMC Public Health 6 (2006) 172-180
32. Ganz P. Erectile dysfunction: pathophysiologic mechanisms pointing to underlying cardiovascular disease. Am J Cardiol 96 (2005) 8M-12M
33. Billups K.L., Bank A.J., Padma-Nathan H., Katz S., and Williams R. Erectile dysfunction is a marker for cardiovascular disease: results of the minority health institute expert advisory panel. J Sex Med 2 (2005) 40-50
34. Barqawi A., O'Donnell C., Kumar R., Koul H., and Crawford E.D. Correlation between LUTS (AUA-SS) and erectile dysfunction (SHIM) in an age-matched racially diverse male population: data from the Prostate Cancer Awareness Week (PCAW). Int J Impot Res 17 (2005) 370-374
35. Kramer H., Han C., Post W., et al. Racial/ethnic differences in hypertension and hypertension treatment and control in the Multi-Ethnic Study of Atherosclerosis (MESA). Am J Hypertens 17 (2004) 963-970
36. Wong M.D., Shapiro M.F., Boscardin W.J., and Ettner S.L. Contribution of major diseases to disparities in mortality. N Engl J Med 347 (2002) 1585-1592
37. Michel M.C., Heemann U., Schumacher H., Mehlburger L., and Goepel M. Association of hypertension with symptoms of benign prostatic hyperplasia. J Urol 172 (2004) 1390-1393
38. Boyle P., and Napalkov P. The epidemiology of benign prostatic hyperplasia and observations on concomitant hypertension. Scand J Urol Nephrol Suppl 168 (1995) 7-12
39. Hammarsten J., and Hogstedt B. Clinical, anthropometric, metabolic and insulin profile of men with fast annual growth rates of benign prostatic hyperplasia. Blood Press 8 (1999) 29-36
40. American Heart Association. Statistical fact sheet-populations: African Americans and cardiovascular diseases [AHA Web site]. http://www.americanheart.org/downloadable/heart/1136405578457AfrAmerican06.pdf Accessed November 30, 2006
41. Ford E.S., Giles W.H., and Dietz W.H. Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Examination Survey. JAMA 287 (2002) 356-359
42. Berger A.P., Bartsch G., Deibl M., et al. Atherosclerosis as a risk factor for benign prostatic hyperplasia. BJU Int 98 (2006) 1038-1042
43. Weisman K.M., Larijani G.E., Goldstein M.R., and Goldberg M.E. Relationship between benign prostatic hyperplasia and history of coronary artery disease in elderly men. Pharmacotherapy 20 (2000) 383-386
44. American Diabetes Association. Total Prevalence of Diabetes & Pre-diabetes [American Diabetes Association Web site]. http://www.diabetes.org/diabetes-statistics/prevalence.jsp Accessed November 29, 2006
45. National Institutes of Health. National Institutes of Health Type 2 Diabetes Fact Sheet [NIH Web site]. http://www.nih.gov/about/researchresultsforthepublic/Type2Diabetes.pdf Accessed December 5, 2006
46. Skelly A.H. Type 2 diabetes mellitus. Nurs Clin North Am 41 (2006) 531-547, vi
47. Glynn R.J., Campion E.W., Bouchard G.R., and Silbert J.E. The development of benign prostatic hyperplasia among volunteers in the Normative Aging Study. Am J Epidemiol 121 (1985) 78-90
48. Michel M.C., Mehlburger L., Schumacher H., Bressel H.U., and Goepel M. Effect of diabetes on lower urinary tract symptoms in patients with benign prostatic hyperplasia. J Urol 163 (2000) 1725-1729
49. Parsons J.K., Carter H.B., Partin A.W., et al. Metabolic factors associated with benign prostatic hyperplasia. J Clin Endocrinol Metab 91 (2006) 2562-2568
50. Michel M.C., Mehlburger L., Bressel H.U., Schumacher H., Schäpers R.F., and Goepel M. Tamsulosin treatment of 19,365 patients with lower urinary tract symptoms: does co-morbidity alter tolerability?. J Urol 160 (1998) 784-791
51. Berger A.P., Deibl M., Leonhartsberger N., et al. Vascular damage as a risk factor for benign prostatic hyperplasia and erectile dysfunction. BJU Int 96 (2005) 1073-1078
52. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 285 (2001) 2486-2497
53. Park Y.W., Zhu S., Palaniappan L., Heshka S., Carnethon M.R., and Heymsfield S.B. The metabolic syndrome prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med 163 (2003) 427-436
54. Hall W.D., Clark L.T., Wenger N.K., et al. The metabolic syndrome in African Americans: a review. Ethn Dis 13 (2003) 414-428
55. Hammarsten J., and Hogstedt B. Clinical, haemodynamic, anthropometric, metabolic and insulin profile of men with high-stage and high-grade clinical prostate cancer. Blood Press 13 (2004) 47-55
56. Kasturi S., Russell S., and McVary K.T. Metabolic syndrome and lower urinary tract symptoms secondary to benign prostatic hyperplasia. Curr Urol Rep 7 (2006) 288-292
57. McVary K.T., Rademaker A., Lloyd G.L., and Gann P. Autonomic nervous system overactivity in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 174 (2005) 1327-1433
58. Rohrmann S., Smit E., Giovannucci E., and Platz E.A. Association between markers of the metabolic syndrome and lower urinary tract symptoms in the Third National Health and Nutrition Examination Survey (NHANES III). Int J Obes (Lond) 29 (2005) 310-316
59. Rohrmann S., DeMarzo A.M., Smit E., Giovannucci E., and Platz E.A. Serum C-reactive protein concentration and lower urinary tract symptoms in older men in the Third National Health and Nutrition Examination Survey (NHANES III). Prostate 62 (2005) 27-33
60. Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care. In: Smedley B.D., Stith A.Y., and Nelson A.R. (Eds) (2002), National Academies Press, Washington, DC